In a different melanoma model, HDAC inhibition was also demonstrated to enhance immunotherapy in triple-negative breast cancer [242], multiple myeloma [243], and B-cell lymphomas. The gene discussed is HDAC9; the disease is triple-negative breast carcinoma.